Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

Economia

COMUNICATO STAMPA - Responsabilità editoriale di Business Wire

GenomSys, the Swiss Startup Disrupting Genomics Information Handling, Closes a CHF 9.3 Million Series A Investment Round

Business Wire

GenomSys, a software company developing ISO compliant technology for efficient processing and sharing of DNA data, announced it has completed its series A investment round. The company raised CHF 9.3 million in this financing, driven by the accelerating development progress of its MPEG-G-based solution for DNA data processing.

The Series A round was led by Preon Capital, the Geneva-based family office of Jari Ovaskainen, Europe’s 2014 Business Angel of the year. Preon was joined by a group of European and U.S. investors, including the Elysia Capital and Pygar family offices, linked respectively to the founder of the European unicorn Advanced Accelerator Applications and to the multinational diagnostic company Diasorin. U.S.-based investors Dolby Family Ventures and Susman Ventures participated in this financing. Pascal Levensohn, Managing Director of these funds, has joined the GenomSys board of directors.

Founded in 2016, GenomSys has developed technology facilitating access to highly-secured personalized medicine services. Its product portfolio includes solutions to compress, browse, store and share genomic information based on the model of digital media compression and streaming technology. Decreasing costs of genomic sequencing are enabling DNA analysis to become mainstream, promising wider accessibility for medical professionals to generate new perspectives. GenomSys’ solutions solve the associated challenges from the ever-increasing data volumes, format proliferation, storage costs and analytic complexity caused by this data explosion.

Based on the newly released ISO MPEG-G Standard, GenomSys’ Software Suite “will bring a dramatic reduction in genomic files’ size, a faster information transfer and more efficient data analysis”, says Claudio Alberti, GenomSys’ co-founder.

As stated by the International Organization for Standardization (ISO), MPEG-G “provides the enabling technology that will allow the community to create an ecosystem of novel, interoperable, solutions in the field of genomic information processing”. MPEG-G will also bring genomic information to personal devices, which will accelerate individuals’ access to personalized medicine, while enforcing strict data-privacy standards.

About GenomSys

GenomSys is a Swiss company developing ISO compliant, enterprise-grade tools and applications for efficient processing and sharing of DNA data, enabling the progress of large-scale genomics and personalized medicine. GenomSys offers solutions to securely compress, browse and store individual DNA on any devices and share them with practitioners for diagnostics, pharmacogenomics, personalized treatments, etc.

For more information, visit our website www.genomsys.com.

Raphaël Bernard
Marketing & Communication Manager
GenomSys SA
+41-(0)-21-691-1000
raphael.bernard@genomsys.com

Permalink: http://www.businesswire.com/news/home/20190918005067/en

Video Economia


Vai al sito: Who's Who

Modifica consenso Cookie